The New GLP-1 That Helped 1 in 4 People Lose 30% of Their Weight! ENICEPATIDE

In Episode 6 of The Downsized’s special ADA 2026 series, Christopher Durham takes a closer look at enicepatide, formerly known as CT-388, Roche and Genentech’s once-weekly GLP-1/GIP obesity drug now moving through clinical development. The Phase 2 results are some of the strongest covered in the series so far. At the highest dose, enicepatide produced 22.5% placebo-adjusted weight loss at 48 weeks, while 26.1% of participants lost 30% or more of their body weight. The trial also reported a 5.9% discontinuation rate due to adverse events, raising an important question: could enicepatide eventually combine major weight loss with a more manageable tolerability profile? Christopher also breaks down the science behind the drug’s biased signaling approach, explains why the popular idea of “GLP-1 receptor burnout” is misleading, and looks at how Roche is positioning enicepatide alongside petrelintide as part of its broader obesity strategy. This video is part of The Downsized’s special series exploring the most important obesity drugs and clinical trial data from the 2026 American Diabetes Association Scientific Sessions. The series looks beyond the headlines at drugs including retatrutide, CagriSema, petrelintide, zenagamtide, Foundayo, enicepatide and more—breaking down the numbers, the science, the side effects, the companies behind them, and what each one could eventually mean for people living with obesity. Christopher and Laraine Durham are GLP-1 patients who have lost more than 150 pounds together. On The Downsized, they share their experiences and break down the latest GLP-1 news, obesity research, clinical trials and treatment developments from a patient perspective. +++++++++++++++++++++++++++++++++++++++ Start your weight loss journey today! We use Mochi Health: https://app.joinmochi.com/eligibility... Use Laraine’s code for $40 off: QIYGO8. Get your Hume BodyPod today and use our exclusive Downsized code for up to 20% total savings! 👉 Use our Code: THEDOWNSIZED Link to purchase: https://humehealth.com//discount/THED... SHOP OUR AMAZON STORE: https://a.co/d/0gGe1MYq BOOK THE DOWNSIZED AT SEA CRUISE 2026: https://thedownsized.org/downsized-at... DOWNSIZED WEBSITE: https://thedownsized.org/ JOIN CLUB DOWNSIZED: https://www.youtube.com/@thedownsized... FOR SPONSORSHIPS, BRAND DEALS & COLLABS: https://thedownsized.org/contact/ +++++++++++++++++++++++++++++++++++++++ 00:00 The New GLP-1 That Helped 1 in 4 People Lose 30% of Their Weight! ENICEPATIDE 01:55 ROCHE'S PORTFOLIO STRATEGY 03:20 WHAT ENICEPATIDE IS 03:52 RECEPTOR BURNOUT IS A MYTH 07:36 THE ADA 2026 DATA — CT388-103 09:48 SAFETY AND TOLERABILITY 11:02 WHAT THIS MEANS FOR SOMEONE LIVING WITH OBESITY 12:21   CT388-104 DIABETES TRIAL 14:07 TAKEAWAY